following a re-submission
linagliptin (Trajenta®) is accepted for use within NHS Scotland.
Indication under review: the treatment of type 2 diabetes mellitus to improve glycaemic control in adults in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
Linagliptin, compared with placebo, improved glycaemic control in adults with type 2 diabetes who had inadequate glycaemic control on an insulin-containing regimen.
SMC has previously accepted linagliptin for restricted use as monotherapy in combination with metformin, and in combination with a sulphonylurea and metformin, This now extends the advice to include its use in combination with insulin.
Download detailed advice163KB (PDF)
Medicine details
- Medicine name:
- linagliptin (Trajenta)
- SMC ID:
- 850/13
- Indication:
- The treatment of type 2 diabetes mellitus to improve glycaemic control in adults in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Endocrine system
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 11 May 2015
SMC has previously accepted linagliptin for restricted use as monotherapy in combination with metformin, and in combination with a sulphonylurea and metformin, This now extends the advice to include its use in combination with insulin. This advice remains valid.